Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...

In the U.S., respiratory syncytial virus (RSV) is responsible for up to 160,000 hospitalizations and 10,000 deaths annually among adults aged 65 and older.

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, improved diagnostics, growing public awareness, and ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.